Practical experience and challenges in nutritional management of glucose transporter 1 deficiency syndrome: Provider survey results

IF 2.8 3区 医学 Q2 CLINICAL NEUROLOGY
Epilepsia Open Pub Date : 2025-02-07 DOI:10.1002/epi4.13135
Diana Lehner-Gulotta, Robyn Blackford, Stacey Bessone, Wesley Lowman, Nicole Haggerty, Chu-Yi Huang, Erika T. Axeen, the Ketogenic Dietitians Research Network
{"title":"Practical experience and challenges in nutritional management of glucose transporter 1 deficiency syndrome: Provider survey results","authors":"Diana Lehner-Gulotta,&nbsp;Robyn Blackford,&nbsp;Stacey Bessone,&nbsp;Wesley Lowman,&nbsp;Nicole Haggerty,&nbsp;Chu-Yi Huang,&nbsp;Erika T. Axeen,&nbsp;the Ketogenic Dietitians Research Network","doi":"10.1002/epi4.13135","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Ketogenic diets (KDs) are recommended as precision therapy for glucose transporter 1 deficiency syndrome (GLUT-1 DS) but there are no recommendations for optimal implementation in this population. We administered an online survey targeting clinicians with experience implementing KDs in GLUT-1 DS, focusing on diet selection, initiation, and management. Respondents were primarily experienced registered dietitian nutritionists (RDNs) from 34 centers in 10 countries. Most reported a preference for carbohydrate counting or ratios under 3:1. KD-related laboratory monitoring (including blood ketones) and vitamin/mineral supplementation did not differ for GLUT-1 DS patients compared to the epilepsy population. Routine use of exogenous ketones was not endorsed for improved ketosis, whereas MCT oil is a commonly used supplement. Respondents overwhelmingly endorsed discussing and implementing gastrostomy feedings to support continued dietary therapy when medically indicated. Most but not all providers (80%) were familiar with the 2020 consensus guidelines. Our survey demonstrates practice variability among experienced dietitians, particularly in diet type and ratio. Identified challenges carry clinical significance, as the diet is a precision therapy in GLUT1-DS. Further research is needed to examine the outcomes of different approaches to KDs in GLUT-1 DS before consensus about the most effective interventions can be reached.</p>\n </section>\n \n <section>\n \n <h3> Plain Language Summary</h3>\n \n <p>Glucose transporter deficiency syndrome is a genetic condition caused by an inability to move sugar (glucose) into the brain, which is needed for proper brain function. Ketogenic diets (low in carbohydrate and high in fat) are the established treatment to help control symptoms. Although the diet is effective, it can be challenging. To understand these challenges, we surveyed experts in ketogenic diet management and found significant variability regarding specifics of how the diet is managed. More research is needed before one approach can be endorsed as most effective.</p>\n </section>\n </div>","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":"10 2","pages":"628-634"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/epi4.13135","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsia Open","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/epi4.13135","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Ketogenic diets (KDs) are recommended as precision therapy for glucose transporter 1 deficiency syndrome (GLUT-1 DS) but there are no recommendations for optimal implementation in this population. We administered an online survey targeting clinicians with experience implementing KDs in GLUT-1 DS, focusing on diet selection, initiation, and management. Respondents were primarily experienced registered dietitian nutritionists (RDNs) from 34 centers in 10 countries. Most reported a preference for carbohydrate counting or ratios under 3:1. KD-related laboratory monitoring (including blood ketones) and vitamin/mineral supplementation did not differ for GLUT-1 DS patients compared to the epilepsy population. Routine use of exogenous ketones was not endorsed for improved ketosis, whereas MCT oil is a commonly used supplement. Respondents overwhelmingly endorsed discussing and implementing gastrostomy feedings to support continued dietary therapy when medically indicated. Most but not all providers (80%) were familiar with the 2020 consensus guidelines. Our survey demonstrates practice variability among experienced dietitians, particularly in diet type and ratio. Identified challenges carry clinical significance, as the diet is a precision therapy in GLUT1-DS. Further research is needed to examine the outcomes of different approaches to KDs in GLUT-1 DS before consensus about the most effective interventions can be reached.

Plain Language Summary

Glucose transporter deficiency syndrome is a genetic condition caused by an inability to move sugar (glucose) into the brain, which is needed for proper brain function. Ketogenic diets (low in carbohydrate and high in fat) are the established treatment to help control symptoms. Although the diet is effective, it can be challenging. To understand these challenges, we surveyed experts in ketogenic diet management and found significant variability regarding specifics of how the diet is managed. More research is needed before one approach can be endorsed as most effective.

Abstract Image

葡萄糖转运蛋白1缺乏综合征营养管理的实践经验和挑战:提供者调查结果。
生酮饮食(KDs)被推荐为葡萄糖转运蛋白1缺乏综合征(GLUT-1 DS)的精确治疗方法,但在这一人群中没有最佳实施方法。我们针对具有在GLUT-1 DS中实施KDs经验的临床医生进行了一项在线调查,重点关注饮食选择、开始和管理。受访者主要是来自10个国家34个中心经验丰富的注册营养师(rdn)。大多数报告偏好碳水化合物计数或比例低于3:1。与癫痫人群相比,GLUT-1 DS患者的kd相关实验室监测(包括血酮)和维生素/矿物质补充没有差异。常规使用外源性酮类并不能改善酮症,而MCT油是一种常用的补充剂。绝大多数受访者支持讨论和实施胃造口喂养,以支持医学指征时继续饮食治疗。大多数(但不是全部)医疗服务提供者(80%)熟悉2020年共识指南。我们的调查显示了经验丰富的营养师的实践差异,特别是在饮食类型和比例方面。确定的挑战具有临床意义,因为饮食是GLUT1-DS的精确治疗。在就最有效的干预措施达成共识之前,需要进一步的研究来检验不同方法治疗GLUT-1 DS的结果。摘要:葡萄糖转运蛋白缺乏综合征是一种由无法将糖(葡萄糖)转移到大脑引起的遗传病,而大脑的正常功能需要葡萄糖。生酮饮食(低碳水化合物和高脂肪)是帮助控制症状的既定治疗方法。虽然这种饮食很有效,但也很有挑战性。为了了解这些挑战,我们调查了生酮饮食管理方面的专家,发现在如何管理饮食的细节方面存在显著差异。在一种方法被认可为最有效之前,还需要进行更多的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Epilepsia Open
Epilepsia Open Medicine-Neurology (clinical)
CiteScore
4.40
自引率
6.70%
发文量
104
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信